US Bancorp DE Has $157,000 Stock Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

US Bancorp DE boosted its stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 56.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,336 shares of the company’s stock after purchasing an additional 1,556 shares during the quarter. US Bancorp DE’s holdings in SpringWorks Therapeutics were worth $157,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the stock. State of New Jersey Common Pension Fund D grew its holdings in SpringWorks Therapeutics by 1.9% in the third quarter. State of New Jersey Common Pension Fund D now owns 46,389 shares of the company’s stock worth $1,486,000 after purchasing an additional 871 shares during the period. KBC Group NV grew its holdings in SpringWorks Therapeutics by 59.1% in the fourth quarter. KBC Group NV now owns 2,634 shares of the company’s stock worth $95,000 after purchasing an additional 978 shares during the period. Quarry LP grew its holdings in SpringWorks Therapeutics by 20.0% in the third quarter. Quarry LP now owns 6,000 shares of the company’s stock worth $192,000 after purchasing an additional 1,000 shares during the period. Venturi Wealth Management LLC acquired a new stake in SpringWorks Therapeutics in the fourth quarter worth $45,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in SpringWorks Therapeutics by 10.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 15,773 shares of the company’s stock worth $570,000 after purchasing an additional 1,488 shares during the period.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. Evercore ISI raised their price target on shares of SpringWorks Therapeutics from $60.00 to $65.00 and gave the stock an “outperform” rating in a report on Wednesday, February 12th. Guggenheim reduced their price objective on shares of SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. HC Wainwright reiterated a “buy” rating and set a $74.00 price objective on shares of SpringWorks Therapeutics in a report on Friday, February 21st. Finally, Wedbush reiterated an “outperform” rating and set a $81.00 price objective on shares of SpringWorks Therapeutics in a report on Thursday, February 20th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, SpringWorks Therapeutics presently has an average rating of “Buy” and a consensus price target of $73.20.

SpringWorks Therapeutics Price Performance

Shares of NASDAQ SWTX opened at $51.14 on Friday. The stock has a market capitalization of $3.83 billion, a P/E ratio of -14.70 and a beta of 0.76. The company has a 50-day moving average price of $45.77 and a 200-day moving average price of $39.16. SpringWorks Therapeutics, Inc. has a 1 year low of $28.21 and a 1 year high of $62.00.

SpringWorks Therapeutics (NASDAQ:SWTX) last released its quarterly earnings results on Thursday, February 20th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.38). SpringWorks Therapeutics had a negative return on equity of 46.74% and a negative net margin of 134.73%. The firm had revenue of $61.55 million for the quarter, compared to analysts’ expectations of $60.53 million. As a group, equities research analysts anticipate that SpringWorks Therapeutics, Inc. will post -2.05 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, COO Badreddin Edris sold 20,000 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $54.23, for a total transaction of $1,084,600.00. Following the transaction, the chief operating officer now directly owns 169,712 shares in the company, valued at approximately $9,203,481.76. The trade was a 10.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Saqib Islam sold 48,000 shares of SpringWorks Therapeutics stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $53.30, for a total transaction of $2,558,400.00. Following the completion of the sale, the chief executive officer now directly owns 1,002,502 shares in the company, valued at approximately $53,433,356.60. This represents a 4.57 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 440,766 shares of company stock worth $24,402,956. 7.61% of the stock is owned by insiders.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.